Western Standard LLC Kinnate Biopharma Inc. Transaction History

Western Standard LLC

  • $106 Million
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
BUY
$7.43 - $13.0 $763,655 - $1.34 Million
102,780 New
102,780 $1.3 Million

Others Institutions Holding KNTE

# of Institutions
2
Shares Held
292K
Call Options Held
0
Put Options Held
0
View Full List

About Kinnate Biopharma Inc.

KNTE Quotes by TradingView
  • Ticker KNTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,145,600
  • Description
  • Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...
More about KNTE
Track This Portfolio

Track Western Standard LLC Portfolio

Follow Western Standard LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Western Standard LLC, based on Form 13F filings with the SEC.

News

Stay updated on Western Standard LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email